[EN] OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES<br/>[FR] COMPOSÉS DE 2-(ARYLMÉTHYL, ARYLOXY OU ARYLTHIO)-N-PYRIDIN-2-YL-ARYLACÉTAMIDE OU DE 2,2-BIS(ARYL)-N-PYRIDIN-2-YL-ACÉTAMIDE ÉVENTUELLEMENT SUBSTITUÉS COMME MÉDICAMENTS POUR LE TRAITEMENT DE MALADIES DES YEUX
申请人:ALLERGAN INC
公开号:WO2011008475A1
公开(公告)日:2011-01-20
The invention provides compounds represented by the formula (I), each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: wherein: A, m, n, p, a, X, Y and Z are defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis and pulmonary edema.
[EN] COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY, METHOD FOR PREPARATION THEREOF, AND USE THEREOF<br/>[FR] COMPOSÉ PRÉSENTANT UNE ACTIVITÉ INHIBITRICE DE L'ERK KINASE, SON PROCÉDÉ DE PRÉPARATION ET UTILISATION ASSOCIÉE<br/>[ZH] 具有ERK激酶抑制活性的化合物、其制备方法和用途
Cobalt Catalyzed α-Hydroxylation of Arylacetic Acid Equivalents with Dioxygen
作者:Rupali Dasharath Shinde、Anil Rajendra Paraskar、Jogendra Kumar、Eliza Ghosh、Tapan Kanti Paine、Sukalyan Bhadra
DOI:10.1021/acs.joc.4c00708
日期:2024.7.5
A cobalt catalyst, under oxidative conditions, facilitates the single electron transfer process in N-pyridyl arylacetamides to form α-carbon-centered radicals that readily react with molecular oxygen, giving access to mandelic acid derivatives. In contrast to the known benzylic hydroxylation approaches, this approach enables chemo- and regioselective hydroxylation at a benzylic position adjacent to